Grant of Options

RNS Number : 8331W

Hemogenyx Pharmaceuticals PLC

21 August 2020

 

21 August 2020

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Grant of Options

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options") to the Company's co-founder and CEO Dr Vladislav Sandler.

The details of the Share Options granted are set out below:

Name	Position	Number of Share Options Granted	Exercise Price (pence)	Vesting Date	Expiry Date
Dr Vladislav Sandler	CEO	5,000,000	7	Immediate	19 August 2025

Following the grant of the Share Options there are, in aggregate, 42,465,786 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 9.79% of the issued ordinary share capital of the Company.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director	[e-mail]
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.	Details of PDMR/person closely associated with them
a)	Name	Dr Vladislav Sandler
b)	Position/status	CEO, Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.07 5,000,000
d)	Aggregated information - Aggregated volume - Price	Price(s) Volume(s) N/A - variable 5,000,000
e)	Date of the transaction	20/08/2020
f)	Place of the transaction	Outside of a trading venue

 

END

 

 

DSHDZGZRRMRGGZG